Tag Isaac Yi Kim MD PhD

Hematology, Oncology, and Palliative Medicine

Second-Line Hormonal for Castrate-Resistant Prostate Cancer

Introduction Androgen deprivation therapy (ADT) using the luteinizing hormone-releasing hormone (LHRH) agonist or antagonist has been the mainstay treatment of systemic hormone-sensitive prostate cancer. Following an initial decline in PSA levels and a clinically significant response rate of 80–90%, majority…

Prostate Cancer
December 24, 2023

Hematology, Oncology, and Palliative Medicine

Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications

Introduction Prostate cancer is the second most frequently diagnosed cancer of men and the sixth leading cause of death in men with close to 258,000 deaths reported worldwide. In the United States alone, prostate cancer is the second leading cause…

Prostate Cancer
December 24, 2023

Hematology, Oncology, and Palliative Medicine

Androgen Receptor

Introduction The androgen receptor (AR) is part of the steroid hormone receptor family of molecules, which also includes the progesterone, estrogen, mineralocorticoid, retinoic acid, thyroid, and vitamin D receptors. The AR is a transcription factor, primarily responsible for mediating the…

Prostate Cancer
December 24, 2023